{
  "id": "5c73acef7c78d69471000088",
  "type": "factoid",
  "question": "Which receptor is targeted by Erenumab?",
  "ideal_answer": "Erenumab is a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28460892",
    "http://www.ncbi.nlm.nih.gov/pubmed/30409109",
    "http://www.ncbi.nlm.nih.gov/pubmed/29263689",
    "http://www.ncbi.nlm.nih.gov/pubmed/28736918",
    "http://www.ncbi.nlm.nih.gov/pubmed/29432219",
    "http://www.ncbi.nlm.nih.gov/pubmed/30360965",
    "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
    "http://www.ncbi.nlm.nih.gov/pubmed/29406534",
    "http://www.ncbi.nlm.nih.gov/pubmed/28644160",
    "http://www.ncbi.nlm.nih.gov/pubmed/29471679",
    "http://www.ncbi.nlm.nih.gov/pubmed/29171821",
    "http://www.ncbi.nlm.nih.gov/pubmed/29697153",
    "http://www.ncbi.nlm.nih.gov/pubmed/28835404",
    "http://www.ncbi.nlm.nih.gov/pubmed/29968151",
    "http://www.ncbi.nlm.nih.gov/pubmed/29878340",
    "http://www.ncbi.nlm.nih.gov/pubmed/30086681"
  ],
  "snippets": [
    {
      "text": "Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) signaling are being explored as prophylactic treatments for migraine. Erenumab (AMG 334) is the first potent, selective, and competitive human mAb antagonist of the CGRP receptor. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28736918",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erratum: Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab [Corrigendum].",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29406534",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PURPOSE OF REVIEW: Monoclonal antibodies (mAbs) targeting the calcitonin-gene-related peptide (CGRP) pathway have been developed for episodic and chronic migraine prevention, either through binding the CGRP ligand (eptinezumab, fremanezumab, galcanezumab) or the CGRP receptor (erenumab). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29432219",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29471679",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29697153",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29263689",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Erenumab is the only mAb that targets the CGRP receptor instead of the ligand, with high specificity and affinity of binding.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29263689",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nWe tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29171821",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We assessed the efficacy and safety of erenumab, a fully human monoclonal antibody against the CGRP receptor, in patients with chronic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28460892",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab is a novel CGRP-receptor antibody with preventive efficacy in migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30360965",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29697153",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab (AMG 334) is the first potent, selective, and competitive human mAb antagonist of the CGRP receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28736918",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE\nTo assess long-term safety and efficacy of anti-calcitonin gene-related peptide receptor erenumab in patients with episodic migraine (EM).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28835404",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, 4 monoclonal antibodies targeting either the CGRP ligand or receptor are being studied for migraine prevention: ALD403 (eptinezumab), AMG 334 (erenumab), LY2951742 (galcanezumab), and TEV-48125 (fremanezumab).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28644160",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Amgen and Novartis are developing erenumab (AIMOVIG\u2122, erenumab-aooe)-a fully human monoclonal antibody calcitonin gene-related peptide (CGRP) receptor antagonist-for the prevention of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29968151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE\nTo determine the potential impact of erenumab, a human anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody, on total exercise time (TET), time to exercise-induced angina, and ST depression in a double-blind, placebo-controlled study in patients with stable angina due to documented coronary artery disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29878340",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Background We evaluated the effect of erenumab, a fully human monoclonal antibody that inhibits the canonical calcitonin gene-related peptide receptor, on migraine-related disability, impact, and health-related quality of life among patients with episodic migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30086681",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "METHODS\nThirteen migraine patients, previously enrolled in erenumab anti-CGRP receptor monoclonal antibody trials, received CGRP in a double-blind, placebo-controlled, randomized cross-over design to investigate their susceptibility to migraine induction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30409109",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Currently, 4 monoclonal antibodies targeting either the CGRP ligand or receptor are being studied for migraine prevention: ALD403 (eptinezumab), AMG 334 (erenumab), LY2951742 (galcanezumab), and TEV-48125 (fremanezumab). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28644160",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Erenumab did not adversely affect exercise time in a high cardiovascular risk population of patients, supporting that inhibition of the canonical CGRP receptor does not worsen myocardial ischemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29878340",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To determine the potential impact of erenumab, a human anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody, on total exercise time (TET), time to exercise-induced angina, and ST depression in a double-blind, placebo-controlled study in patients with stable angina due to documented coronary artery disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29878340",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "calcitonin gene-related peptide receptor"
}